CYPHERPUNK TECHNOLOGIES INC. (CYPH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 1.74M USD | Liabilities, Current |
| Cash and equivalents | 7.62M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.74M | $7.62M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $3.00M | $6.69M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $4.56M | $14.04M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $8.70M | $9.69M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $14.32M | $18.13M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $14.04M | $32.71M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $14.08M | $47.25M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $16.09M | $62.82M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $15.60M | $78.48M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $10.44M | $54.92M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $12.68M | $70.64M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $11.04M | $80.74M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $11.76M | $91.42M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $10.31M | $102.04M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $11.22M | $65.50M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $11.72M | $78.31M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $10.41M | $90.88M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $7.34M | $103.22M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $9.99M | $114.92M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $11.26M | $124.77M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $8.06M | $35.73M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $7.39M | $43.49M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $7.37M | $52.07M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.71M | $57.98M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $6.84M | $64.89M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $9.20M | $25.46M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $8.49M | $3.89M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $7.93M | $10.06M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $8.46M | $15.75M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $8.19M | $21.71M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $6.45M | $16.28M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $6.05M | $23.25M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $6.03M | $30.48M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.84M | $35.38M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.08M | $25.74M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $5.99M | $14.20M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $4.38M | $17.17M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $4.61M | $23.80M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $36.16M | $793.00K | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $3.13M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $405.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |